Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, October 2001, p. 2695-2702, Vol. 45, No. 10
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.10.2695-2702.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
RL-37, an Alpha-Helical Antimicrobial Peptide of
the Rhesus Monkey
Chengquan
Zhao,1
Tung
Nguyen,1
Lee Ming
Boo,1
Teresa
Hong,1
Cesar
Espiritu,1
Dmitri
Orlov,1
Wei
Wang,1
Alan
Waring,1,2 and
Robert I.
Lehrer1,3,*
Departments of
Medicine1 and
Pediatrics2 and the Molecular
Biology Institute,3 UCLA School of Medicine,
Los Angeles, California 90095
Received 12 February 2001/Returned for modification 3 May
2001/Accepted 28 June 2001
 |
ABSTRACT |
Rhesus monkey bone marrow expresses a cathelicidin whose C-terminal
domain comprises a 37-residue alpha-helical peptide (RL-37) that
resembles human LL-37. Like its human counterpart, RL-37 rapidly
permeabilized the membranes of Escherichia coli ML-35p and
lysed liposomes that simulated bacterial membranes. When tested in
media whose NaCl concentrations approximated those of extracellular fluids, RL-37 was considerably more active than LL-37 against staphylococci. Whereas human LL-37 contains five acidic residues and
has a net charge of +6, rhesus RL-37 has only two acidic residues and a
net charge of +8. Speculating that the multiple acidic residues of
human LL-37 reduced its efficacy against staphylococci, we made a
peptide (LL-37 pentamide) in which each aspartic acid of LL-37 was
replaced by an asparagine and each glutamic acid was replaced by a
glutamine. LL-37 pentamide's antistaphylococcal activity was
substantially greater than that of LL-37. Thus, although the precursor
of LL-37 is induced in human skin keratinocytes by injury or
inflammation, its insufficiently cationic antimicrobial domain may
contribute to the success of staphylococci in colonizing and infecting
human skin.
 |
INTRODUCTION |
Cathelin is a porcine leukocyte
peptide with 96 amino acid residues. Its name is an acronym for
cathepsin L inhibitor and reflects an early belief that it was a
cysteine-protease inhibitor (28). Subsequently, the
cathelin sequence was recognized as a conserved domain in the
precursors of many mammalian antimicrobial peptides that are now
collectively known as "cathelicidins" (42).
Cathelin-associated antimicrobial peptides are structurally diverse
(14). Many have an amphipathic alpha-helical structure, while others are
-sheet peptides with intramolecular cystine disulfide bonds and some have numerous proline or tryptophan residues. The bovine cathelicidin peptides include a cyclic dodecapeptide (29), a tryptophan-rich tridecapeptide called indolicidin
(8, 31), two proline- and arginine-rich bactenecins
(10, 30), and at least three alpha-helical bovine myeloid
antimicrobial peptides (BMAPs) (13, 33). Porcine
cathelicidin peptides include three alpha-helical porcine myeloid
antimicrobial peptides (PMAPs) (35, 38, 43), five
-sheet protegrins, (20, 44), and several proline-rich
molecules (2, 15, 28). Sheep and goats also possess
multiple cathelicidins (3, 17, 24, 32).
In contrast to the above, only a single cathelicidin, human cationic
antimicrobial peptide of 18 kDa (hCAP-18), is currently known to
exist in humans. This propeptide, whose C-terminal domain constitutes
the 37-residue antimicrobial peptide called LL-37, is produced
constitutively by precursors of neutrophils in the bone marrow and is
stored within the secondary (specific) granules of the neutrophil
(33). hCAP-18 is also produced constitutively by
epididymal epithelial cells, so that large concentrations of hCAP-18
are present in normal seminal plasma and the peptide coats the surfaces
of normal spermatozoa (25). Recent evidence suggests that
certain human lymphocyte populations also express LL-37
(1).
The gene for hCAP-18 contains putative interleukin-6-responsive
promoter elements (12), and in vivo hCAP-18 expression is induced in normal skin keratinocytes after infection, inflammation, or
injury (11). Squamous epithelia of the human mouth,
tongue, esophagus, cervix, and vagina also express hCAP-18 mRNA and
peptide, which suggests a more general role for the peptide in
protecting surface epithelia (12). A recent study compared
human LL-37 to the alpha-helical cathelicidin peptides of several other
mammals and found that the human peptide was much less potent than
rabbit CAP-18 or sheep SMAP-29 (39). In this group of
alpha-helical cathelicidin peptides, activity appeared to correlate
with net positive charge and the presence of a hydrophobic gradient
along the peptide backbone.
Because rhesus macaques (Macacca mulatta) are widely used in
experimental studies, we sought homologues of human hCAP-18 in rhesus
bone marrow. Anticipating that the human and rhesus cathelin domains
would be similar, we used the previously described human cathelin
sequence to probe for the corresponding rhesus cathelicidin mRNA. We
isolated a single molecular species that encoded the alpha-helical
peptide whose properties are described herein.
 |
MATERIALS AND METHODS |
cDNA cloning.
Rhesus bone marrow was obtained from macaques
that were euthanatized at the California Regional Primate Center,
Davis, for reasons unrelated to this study. Total RNA was purified by
the Tri-Reagent procedure according to the protocol of the manufacturer (Molecular Research Center, Cincinnati, Ohio). Briefly, fresh bone
marrow was mixed with 3.75 ml of Tri-Reagent BD and after phase
separation occurred, and the aqueous phase was transferred to a fresh
tube and reserved for RNA purification. Rapid amplification of 3' cDNA
ends (3'RACE) was done with a kit (Gibco BRL, Gaithersburg, Md.), using 1 µg of total monkey RNA and 1 µl of adapter primer (10 µl) to obtain first-strand cDNA. A sense primer (5'
CGGCCATGAAGACCCAAAGGAATGG) that corresponded to nucleotides 7 to
31 of human LL-37 was synthesized. PCR was done in a 50-µl volume,
using 10% of the above cDNA product, 10 pmol of each abridged
universal amplification primer (AUAP; Gibco Life Technologies,
Rockville, Md.), and sense primer. The reaction was performed for 32 cycles in a GeneAmp PCR System 2400 (Perkin-Elmer, Palo Alto, Calif.)
with the following temperatures and times: 94°C, 20 s; 55°C,
20 s, 72°C, 40 s. After electrophoresis on 0.8% agarose
gels, a 600-bp product was purified and cloned into PCR2.1 vector
(Invitrogen, Carlsbad, Calif.). Sequencing was performed with an
Applied Biosystem 373 DNA Sequencer (Perkin-Elmer) at the UCLA
DNA Sequencing Facility, using the fluorescein-labeled dideoxynucleotide terminator method.
Peptide synthesis and purification.
The peptides (Table
1) were synthesized at a 0.25-mmol scale with a Perkin-Elmer ABI
431 A synthesizer, using prederivatized polyethylene glycol polystyrene
serine resin (PerSeptive Biosystems, Framingham, Mass.), FastMoc
chemistry, and single coupling for all residues. After purification by
reverse-phase high-performance liquid chromatography, each peptide
appeared homogeneous, and for each the mass as measured by
electrospray ionization (ESI) mass spectrometry agreed well with
its theoretical mass.
Antibacterial assays.
The antimicrobial properties of RL-37
were tested by a two-stage radial diffusion assay (22,
34). Briefly, approximately 4 × 106 CFU of
mid-logarithmic-phase organisms was dispersed into 10 ml of a molten
(43°C) underlay gel mixture consisting of 10 mM sodium phosphate (pH
7.4), Trypticase soy broth power (0.3 mg/ml; Difco, Detroit, Mich.),
and 1% (wt/vol) Sigma A6013 agarose, with or without additional 100 mM
NaCl. The mixture was vortexed and decanted into a petri dish. Multiple
sample wells were punched in this underlay gel after it had solidified.
Serial peptide dilutions containing 250, 79.1, 25, 7.91, 2.5, and 0.79 µg of peptide per ml were prepared in 0.01% acetic acid, to which
0.1% human serum albumin had been added to minimize adsorptive peptide
loss. Aliquots (8 µl) of these dilutions were applied to the wells.
After 3 h of incubation at 37°C, overlay gels that contained 60 mg of
Trypticase soy broth powder/ml in 1% (wt/vol) agarose were poured atop
the underlay gels. After the plates were incubated overnight at 37°C,
the resulting clear zones were measured to the nearest 0.1 mm after
overnight incubation and were expressed in units (1 mm = 10 U)
after subtracting the well diameter (3.2 mm). We then either plotted
the log10 peptide concentration (X axis) against
the zone diameter (Y axis) or performed a linear regression
analysis of the data in order to determine the X intercept,
whose value represented the minimal effective concentration (MEC). The
procedure and its rationale are fully described elsewhere
(34) and were compared to conventional NCCLS-type procedures in an earlier paper published in this journal
(40).
LPS binding.
Quantitative chromogenic Limulus
amoebocyte lysate assays were performed with a QCL-1000 kit (Bio
Whittaker, Walkersville, Md.). Incubation were done in flat-bottom,
nonpyrogenic 96-well tissue culture plates (catalog no. 3596; Costar,
Cambridge, Mass.). Peptides were prepared in endotoxin-free, acidified
water (0.01% acetic acid) and serially diluted in this vehicle. In
step 1, the peptide of interest was incubated at 37°C for 30 min with 0.5 endotoxin units/ml of E. coli 0111:B4
lipopolysaccharide (LPS) in a volume of 50 µl. Then (step 2), 50 µl
of Limulus amebocyte lysate was added, and the mixture was
incubated for 10 min at 37°C. Finally (step 3), 100 µl of the
chromogenic substrate
(acetyl-Ile-Glu-Ala-Arg-p-nitroanilide) was added and the
incubation was continued for 30 min. During this time, the liberation
of p-nitroaniline was monitored every 60 s at 405 nm,
with a SpectraMax 250 Kinetic Microplate Spectrophotometer (Molecular
Devices, Sunnyvale, Calif.). The change in optical density (
OD)
between 11 and 17 min was calculated for an LPS-free control sample
that contained the peptide, and this value was subtracted from the
OD between 11 and 17 min of the experimental sample, which contained
the peptide and LPS. The percent binding (inhibition) was calculated
from the quotient (Q) of the
OD with peptide divided by
the
OD peptide-free controls, with the formula: (1
Q) × 100. Performing the assays kinetically allowed us
to monitor spontaneous procoagulant activation and verify that the peptide did not activate Limulus procoagulant directly when
LPS was absent and that the peptide was not contaminated with LPS. In
the absence of peptide, the
OD was a linear function of the amount
of LPS added in step 1, between 0.05 and 1.0 endotoxin units of LPS.
Bacterial membrane permeabilization.
To assess the ability
of RL-37 to permeabilize the inner and outer membranes of
Escherichia coli ML-35p, we modified a previously described
spectrophotometric procedure (21) for fluorescent substrates, because PADAC, the chromogenic
-lactamase substrate [7-(thieny-2-acetamido)-3-(2-(4-N,N-dimethylaminophenylazo)-pyrididiummethyl)-3-cephem-4-carboxylic acid] was no longer commercially available. Its fluorogenic
replacement was CCF2-free acid (mass, 864 Da) was purchased from
Aurora Bioscience (San Diego, Calif.). This molecule's cephalosporin
core links a 7-hydroxycoumarin residue to a fluorescein moiety, such
that fluorescence resonance energy transfer occurs when the coumarin is
excited (45). Cleavage of the cephalosporin's
-lactam
ring results in spontaneous elimination of the 3' fluorescein, with an
attendant decrease in fluorescence resonance energy transfer. We
replaced ONPG
(O-nitrophenyl-
-D-galactopyranoside), a
chromogenic
-galactosidase substrate, with DiFMUG (6,8 difluoro-4-methylumbelliferyl
-D-galactopyranoside),
which was purchased from Molecular Probes (Eugene, Oreg.). Both
fluorogenic substrate stock solutions (200 µM) were prepared in 10 mM
sodium phosphate buffer (pH 7.4), and the assays were performed in
black, 96-well plates with lids (Corning, Corning, N.Y.). Their
hydrolysis products were detected with an f-max fluorescence
microplate reader (Molecular Devices Corp.), using SOFTmaxPRO software
supplied by the manufacturer. An excitation wavelength of 380 nm and
emission wavelength of 460 nm was suitable for both substrates.
The final incubation medium contained 10 mM sodium phosphate buffer,
100 mM NaCl, and 0.3 mg of Trypticase soy broth powder per ml.
Incubation wells (final volume, 200 µl) also contained 10 µM
substrate (CCF2 or DiFMUG); 2.5 × 107 CFU of washed,
stationary-phase E.coli ML-35p cells; and various concentrations of the peptide of interest or an equivalent volume of
acidified water (negative controls). Assays were run at 37°C, with
10 s of shaking every minute. Reactions were started by adding the bacteria.
Liposome studies.
Lipids were purchased from Avanti Polar
Lipids (Alabaster, Ala.). A cationic thiadicarbocyanine
dye
N,N'-di(3-trimethylammoniumpropyl)thiadicarbocyanine tribromide
was from Molecular Probes. Liposomes simulating
E. coli membranes were prepared from
1-palmitoyl-2-oleoyl-sn- glycero-3-phosphatidylethanolamine (POPE),
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol (POPG), and cardiolipin (CL) in a 3:1:0.44 molar ratio (POPE-POPG-CL) Liposomes that simulated Staphylococcus aureus membranes
were prepared by combining POPG and CL in a 3:1 ratio
(16). Thiadicarbocyanine dye-encapsulated lipid vesicles
were prepared by extrusion. For each preparation, around 20 mg of the
lipid mixture was dissolved in 2 ml of chloroform in a glass tube. The
solvent was removed under streaming argon and further dried for 2 h under vacuum. The lipids were hydrated and then dispersed into 2 ml
of 10 mM phosphate buffer, pH 7.4, containing 0.5 mg of the dye per ml. This dispersion was treated by 10 cycles of freezing in liquid nitrogen
followed by thawing in a 50°C water bath. The milky product was
passed seven times through a 100-nm polycarbonate filter mounted in an
Avanti Mini-extruder. Unencapsulated dye was removed by passing the
liposomes through a Sephadex G-50 column. The final concentration of
the lipid was 67 µg/ml.
Graded amounts of RL-37, LL-37, and PG-1 were added to each well to
obtain final peptide concentrations between 3 to 40 µM. The 96-well
plate was incubated at room temperature for 10 min. Fluorescence
measurements were made with a SpectraMAX Gemini XS Microplate
Spectrophotometer (Molecular Devices), with excitation at 653 nm and
emission at 674 nm. The no-lysis control contained liposomes in
phosphate buffer without peptide. The 100% lysis control contained
liposomes with 0.1% Triton X-100. The percentage of peptide-induced
liposome lysis was calculated using the following equation, where
F represents the fluorescence intensity of samples that
contained peptides, F0 is the fluorescence in
the absence of peptides, and Ft is the
fluorescence in the presence of 0.1% Triton X-100:
(F
F0)/(Ft
F0) × 100.
CD spectroscopy.
Circular dichroism (CD) spectra were taken
at 25°C on a model 62DS spectropolarimeter (AVIV Associates,
Lakewood, N.J.) in a rectangular 0.1-mm-path-length cell that
contained either 10 mM phosphate buffer, pH 7.4; 50% trifluoroethanol;
sodium dodecyl sulfate; unilamellar liposomes (~100 nm diameter) in
10 mM phosphate buffer, pH 7.4; or an LPS dispersion (40).
The instrument was calibrated with (+)-10-camphorsulfonic acid
(18). Extruded liposomes that simulated bacterial
membranes were prepared with a LipoSoFast extruder (Avestin, Ottawa,
Canada) as previously described (16). The helical content
of the peptide in various solvents was estimated from its mean residue
ellipticity by the following equation6: % helix = [
]MRE222/(
39,500 [1
(2.57/n)])
deg cm2 dmol
1.
Nucleotide sequence accession number.
The RL-37 sequence was
deposited in GenBank, as accession no. AF181954.
 |
RESULTS |
cDNA cloning of the rhesus cathelicidin.
The primary
nucleotide and inferred protein sequences of the rhesus cathelicidin
peptide, preproRL-37, are shown in Fig.
1. The cDNA sequence contained a 510-bp
open reading frame that encoded a 170-residue prepropeptide with a mass
of 18,861 Da and an isoelectric point of 10.06. Its 30-amino-acid
signal peptide was followed sequentially by a 103-residue cathelin
domain and the 37-residue RL-37 domain. Overall, the rhesus cDNA
sequence was 92% identical to that of human hCAP-18. The signal
sequences differed at only 5 bp (5.6%), the cathelin domains differed
at only 16 bp (5.2%), and the antimicrobial peptide domains, differed
at only 16 bp (14.4%).

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 1.
cDNA sequence of the rhesus monkey cathelicidin, RL-37.
The precursor has 170 residues, a mass of 18,861 Da, and a pI of
10.06. The predicted signal sequence (33 residues) is underlined, and
the expected mature peptide is shown in bold face type. The stop codon
is indicated by asterisks, and the polyadenylation site is indicated by
italics.
|
|
Rhesus preproRL-37 and human preproLL-37 peptide sequences are shown in
Fig. 2. Overall, 146 of the 170 residues
(85.9%) are identical. In the signal sequences, 28 of 30 (93.3%) of
the residues are identical, as are 94 of 103 of the residues in the
cathelin domains. Only 25 of the 37 residues (67.6%) in the respective antimicrobial peptide domains are identical. RL-37 has 10 positively charged residues (three arginines and seven lysines) and two negatively charged residues (one aspartic acid and one glutamic acid), giving it a
net charge of +8. Human LL-37 contains 11 positively charged residues
(five arginines and six lysines), but also has five negatively charged
ones (two aspartic and three glutamic acids), making its net
charge + 6.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 2.
Comparison of rhesus and human cathelicidin peptides.
Both signal peptides (underlined) have 30 residues, of which 28 (93.3%) are identical. Both cathelin domains have 101 residues, of
which 93 (92%) are identical. The mature domains (dotted underlined)
of RL-37 and LL-37 both contain 37 residues, of which 25 (67.6%) are
identical. Mature rhesus RL-37 has a mass of 4,100.9 Da, a theoretical
pI of 11.20, and a net charge of +8. Mature human LL-37 has a mass of
4527.34, a pI of 10.61, and a net charge of +6. A vertical line
connects identical residues, and a plus sign identifies conservative
substitutions. Residues that differ in the human and rhesus peptides
are shown in boldface type.
|
|
Antimicrobial activity.
When we compared the antimicrobial
activities of RL-37 and LL-37, their relative activities depended both
on the organism being tested and the salinity of the test medium.
Neither peptide was active (MEC >250 µg/ml) against Candida
albicans, even when tested under our least-stringent conditions,
without added NaCl. The human and rhesus peptides showed similar
potency against E. coli ML-35p, Pseudomonas
aeruginosa, and Listeria monocytogenes, and both
retained substantial activity against these organisms even in underlay
gels supplemented with 200 mM NaCl (Fig.
3).

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
Activity against E. coli, P. aeruginosa, and
L. monocytogenes. Radial diffusion assays were performed in
underlay gels that contained different amounts of NaCl (0 mM, 100 mM,
or 200 mM), in addition to their common basic ingredients (10 mM sodium
phosphate buffer, pH 7.4; Trypticase soy broth powder, 0.3 mg/ml; and
1% [wt/vol] agarose).
|
|
The most notable differences between the peptides were evident when we
tested staphylococci in the presence of 100 or 175 mM NaCl. With each
of the four test strains (two S. aureus, one Staphylococcus epidermidis and one methicillin resistant
S. aureus), RL-37 was significantly more potent than LL-37
under such conditions. This difference disappeared when the peptides
were studied under low-salt conditions (no added NaCl) and was
magnified when the NaCl concentration of the underlay gel was raised to
175 mM (Table 2).
Table 2 also includes our results with LL-37 pentamide, a peptide
whose primary sequence (Table 1) was identical to that of LL-37 except
that each aspartic acid of LL-37 was replaced by asparagine, and each
glutamic acid in LL-37 was replaced by a glutamine. The pentamide
variant was significantly more effective than LL-37, and its potency
equaled or exceeded that of RL-37. The activity of LL-37 and LL-37
pentamide against several additional organisms is shown in Table
3. These studies were done in 100 mM
NaCl. Although RL-37 was somewhat more effective than LL-37 against
Klebsiella pneumoniae and P. aeruginosa, the
differences between the peptides were not nearly as striking as those
seen with staphylococci. Surprisingly, RL-37 was considerably less active than LL-37 against group B streptococci.
Mechanism of activity.
Many antimicrobial peptides act, at
least in part, by permeabilizing the membranes of their microbial
targets. This property can be tested conveniently in intact bacteria by
monitoring the ability of normally impermeant substrates to reach the
periplasmic
-lactamase and cytoplasmic
-galactosidase enzymes of
E. coli ML-35p. Figure 4 shows
that 2.5 µg of RL-35 per ml rapidly permeabilized both the outer and
inner membranes of this organism.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 4.
Membrane permeabilization. Stationary-phase E. coli ML-35P (2.5 × 107 CFU/ml) was suspended in
10 mM sodium phosphate buffer, pH 7.4, containing 100 mM NaCl, 0.3 mg
of Trypticase soy broth powder per ml, and fluorogenic substrates for
-lactamase and -galactosidase. Fluorescence monitoring began
immediately after the addition of 2.5 µg of RL-37. Controls were
incubated under identical conditions but in the absence of the
peptide.
|
|
Liposome lysis assay.
The ability of RL-37 and LL-37 to lyse
phospholipid liposomes whose compositions simulated the membranes of
gram-negative and gram-positive bacteria is illustrated in Fig.
5. For both types of liposomes, RL-37 was
more potent than LL-37. Neither peptide was hemolytic for human
erythrocytes, even when tested at a maximal concentration of 80 µg/ml
(data not shown).

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 5.
Liposome lysis. A cationic thoadicarbocyanine dye was
encapsulated in liposomes formulated to resemble gram-positive and
gram-negative membranes. Fluorescence measurements were made 10 min
after the addition of peptides.
|
|
LPS binding.
The ability of the study peptides (LL-37, RL-37,
and LL-37 pentamide) to bind E. coli 0111:B4 LPS is shown in
Fig. 6. Polymyxin B, a lipopeptide
antibiotic well known to bind LPS, served as a positive control. The
respective concentrations of these peptides that bound half of the
added LPS (the 50% effective concentration [EC50]) is an
index of their binding affinity for this ligand. Thus, LL-37
(EC50, 420 nM) had an approximately 3-fold greater affinity
for LPS than did LL-37 pentamide (EC50, 1.46 µM) and a
10-fold greater affinity than did RL-37 (EC50, 4.44 µM).
The affinity of polymyxin B for LPS (EC50, 60 nM) was
~7-fold higher than that of LL-37, ~25-fold higher than that of
LL-37 pentamide, and ~75-fold higher than that of RL-37.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 6.
LPS binding. We used a chromogenic Limulus
amoebocyte assay to obtain binding isotherms for E. coli
0111:B4 lipopolysaccharide. The peptides examined included polymyxin B,
LL-37, LL-37 pentamide, RL-37, and rabbit CAP-18 (another LPS binding
cathelicidin). The EC50 (i.e., the peptide concentrations
that bound 50% of the LPS) are shown and provide an approximate
binding constant.
|
|
Secondary structural analysis.
CD measurements were done in
several systems, and representative spectra are shown in Fig.
7. RL-37 showed very little helical structure when dissolved in aqueous buffer (7.9% helix) or in normal
saline solution (8% helix). In trifluoroethanol (a structure promoting
solvent) detergent micelles, or dispersed phospholipids or
lipopolysaccharides, changes characteristic of a helical conformation appeared: dichroic minima at 222 and 208 nm with a well-defined maximum
at 193 nm. RL-37 was about 40% helix (5, 41) in
trifluoroethanol-containing buffer, 43.2% helix in sodium dodecyl
sulfate micelles, 34.6% helix in phospholipid dispersions that
simulated gram-negative bacterial membranes, and 35.5% helical in LPS
dispersions.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 7.
CD. Spectra labeled A, B, and C are shown. Spectrum A
was obtained in 10 mM sodium phosphate buffer, pH 7.4. Spectrum B was
obtained in liposomes that contained POPE-POPG-cardiolipin in a
3:1:0.44 molar ratio that simulated gram-negative membranes. These
liposomes were dispersed in 10 mM sodium phosphate buffer, pH 7.4. Spectrum C was obtained in a dispersion of diphosphoryl lipid A from
E. coli F583 (Sigma) in 10 mM sodium phosphate buffer. In
each experiment, the peptide concentration was 120 µM and the
lipid-to-peptide molar ratio was 20:1.
|
|
 |
DISCUSSION |
The content of antimicrobial peptides in mammalian
leukocytes shows considerable interspecies variation. For example,
-defensins are abundant in the neutrophils of humans, rats, rabbits,
and guineas pigs, but only
-defensins occur in bovine neutrophils. Furthermore, in our previous studies of neutrophils from laboratory mice, horses, sheep, goats and pigs, we have noted that these cells
apparently lack defensins completely (7, 9, 20, 32). There
is similar interspecies variation with respect to cathelicidins.
Whereas the granulocytes of cattle, pigs, sheep, and goats contain many
different cathelicidin molecules, human neutrophils contain only
one
hCAP-18, the cathelicidin that carries the 37-residue peptide
called LL-37.
It was recently reported that the bone marrow of M. mulatta,
the rhesus monkey, expresses multiple
-defensins (36)
as well as a remarkable circular peptide (RTD-1) derived from two
truncated and spliced
-defensin precursors (37).
Nothing has been reported about the cathelicidins of this species,
except for a recent paper, which described a rhesus cathelicidin that
was identical to human hCAP-18 at the nucleotide and peptide
level (4). Like this report, we found that only a single
cathelicidin, the precursor of RL-37, was expressed in the bone marrow
of M. mulatta. However, as discussed above, only 146 of the
170 residues (85.9%) in the rhesus and human sequences were identical.
The signal sequence and cathelin domain of RL-37 showed the typical
sequence conservation characteristic of cathelicidins. The amino
acid sequence of RL-37's cathelin domain revealed 66 to 78% identity
to the sequences of horse cathelicidin 2 (78%), rabbit CAP-18 (70%),
sheep or goat bactenecin-5 (69%), and porcine prophenin-2 (66%). Even
RL-37 signal sequence was 70 to 77% identical to cathelicidins from
horse, sheep, and goat.
Although RL-37 generally resembled LL-37 in its size, sequence, and
ability to adopt an alpha-helical structure, we were intrigued by its greater potency against staphylococci and sought
to learn why this occurred. Because electrostatic interactions
between cationic antimicrobial peptides and the negatively charged
surface molecules (e.g., lipoteichoic acid and/or acidic phospholipids) of staphylococci are likely to influence their antimicrobial
properties, we modified LL-37 in a manner that simultaneously increased
its net positive charge and eliminated its five acidic residues,
without greatly changing its overall configuration (Table 1). The
resulting peptide, LL-37 pentamide, had greatly improved potency
against S. aureus and methicillin-resistant S. aureus (Table 2).
These findings were consistent with the recent findings of Peschel et
al. on staphylococcal dlt gene mutants (27).
These investigators reported that the teichoic acids of these mutants were deficient in D-alanine, causing these bacterial
macromolecules to have an increased negative surface charge and to show
increased binding of cationic (positively charged) proteins relative to wild-type bacteria. These dlt mutants were more sensitive to
human
-defensins HNP 1 to 3 and to other cationic antimicrobial
peptides. Wild-type strains with additional copies of the
dlt operon were less sensitive to these antimicrobial
peptides, presumably because their teichoic acids bound the peptides
less well. We speculate that the altered charge balance of LL-37
pentamide allowed it to bind (lipo)teichoic acid and anionic
phospholipids more effectively and that one or both of these properties
was responsible for its increased effectiveness against staphylococcus.
This is entirely consistent with Peschel's recent description of a
mutant Staphylococcus strain that was hypersensitive to host
defense peptide due to its inability to modify phosphatidylglycerol
with L-lysine
a reaction that reduces the negative membrane
surface charge in wild-type S. aureus (26).
They suggested that intrinsic MprF-mediated peptide resistance was most
likely based on repulsion of the cationic peptides and that
mprF inactivation led to increased binding of antimicrobial
peptides by the bacteria.
Skin certainly must be the saltiest surface of the body, since sweat
continually delivers salt to the body surface, where its NaCl content
undergoes concentration by evaporation (23). Staphylococci
normally reside on the skin surface, and most grow well in the presence
of high salt concentrations. Normal human skin can express at least two
different classes of antimicrobial peptides,
-defensins (HBDs) and
the cathelicidin hCAP-18. Whereas the HBD-1 is expressed
constitutively, HBD-2 and hCAP-18 are expressed after induction by
signals associated with inflammation, injury, and infection. Since
defensins (19) and LL-37 (40) are not very
effective against staphylococci in the presence of the concentrations of NaCl found in extracellular fluids or at the skin surface, it is not
surprising that S. epidermidis can colonize human skin and
that recruitment of neutrophils is frequently needed to deal with
staphylococcal invasion. Neutrophils are effective because they can
expose ingested staphylococci to high concentrations of oxidants as
well as to very high concentrations of
-defensins and other
antimicrobial molecules that are translocated to its phagocytic vacuoles.
Because we saw a pronounced inhibitory effect of salt on the
antimicrobial properties of LL-37 only in our studies with
staphylococci, the accumulation of LL-37 in and between viable
keratinocytes should still form an effective chemical barrier that
would protect against invasion by many microorganisms. Our data clearly
show that a high-salt ionic environment, like that found in bulk
extracellular fluid, is inimical to the antistaphylococcal activity of
LL-37. However, if LL-37 were to accumulate extracellularly in the
spaces between keratinocytes, this polycationic peptide might lower the ambient sodium and chloride concentrations of this interstitial microenvironment via a Donnan equilibrium, possibly augmented by active
keratinocyte-mediated ion transport. While these musings about
interstitial microenvironments are purely speculative, they might
eventually prove to be accurate. If so, then LL-37 or the similarly
polycationic- and salt-sensitive human
-defensins might play a
larger part in deterring staphylococcal invasion than our data would
otherwise suggest.
 |
ACKNOWLEDGMENTS |
We thank Jennifer Guerrero for assistance in performing
antimicrobial assays.
This work was supported, in part, by National Institutes of Health
grants AI 22839 and AI 43934.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, Room CHS 37-062, UCLA School of Medicine, 10833 LeConte Ave., Los Angeles, CA 90095-1690. Phone: (310) 825-5340. Fax: (310) 206-8766. E-mail: rlehrer{at}mednet.ucla.edu.
 |
REFERENCES |
| 1.
|
Agerberth, B.,
J. Charo,
J. Werr,
B. Olsson,
F. Idali,
L. Lindbom,
R. Kiessling,
H. Jornvall,
H. Wigzell, and G. H. Gudmundsson.
2000.
The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations.
Blood
96:3086-3093[Abstract/Free Full Text].
|
| 2.
|
Agerberth, B.,
J. Y. Lee,
T. Bergman,
M. Carlquist,
H. G. Boman,
V. Mutt, and H. Jornvall.
1991.
Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides.
Eur. J. Biochem.
202:849-854[Medline].
|
| 3.
|
Bagella, L.,
M. Scocchi, and M. Zanetti.
1995.
cDNA sequences of three sheep myeloid cathelicidins.
FEBS Lett.
376:225-228[CrossRef][Medline].
|
| 4.
|
Bals, R.,
C. Lang,
D. J. Weiner,
C. Vogelmeier,
U. Welsch, and J. M. Wilson.
2001.
Rhesus monkey (Macaca mulatta) mucosal antimicrobial peptides are close homologues of human molecules.
Clin. Diagn. Lab. Immunol.
8:370-375[Abstract/Free Full Text].
|
| 5.
|
Bruch, M. D.,
M. M. Dhingra, and L. M. Gierasch.
1991.
Side chain-backbone hydrogen bonding contributes to helix stability in peptides derived from an alpha-helical region of carboxypeptidase A.
Proteins
10:130-139[CrossRef][Medline].
|
| 6.
|
Chen, Y. H.,
J. T. Yang, and K. H. Chau.
1974.
Determination of the helix and beta form of proteins in aqueous solution by circular dichroism.
Biochemistry
13:3350-3359[CrossRef][Medline].
|
| 7.
|
Couto, M. A.,
S. S. Harwig,
J. S. Cullor,
J. P. Hughes, and R. I. Lehrer.
1992.
Identification of eNAP-1, an antimicrobial peptide from equine neutrophils.
Infect. Immun.
60:3065-3071[Abstract/Free Full Text].
|
| 8.
|
Del Sal, G.,
P. Storici,
C. Schneider,
D. Romeo, and M. Zanetti.
1992.
cDNA cloning of the neutrophil bactericidal peptide indolicidin.
Biochem. Biophys. Res. Commun.
187:467-472[CrossRef][Medline].
|
| 9.
|
Eisenhauer, P. B., and R. I. Lehrer.
1992.
Mouse neutrophils lack defensins.
Infect. Immun.
60:3446-3447[Abstract/Free Full Text].
|
| 10.
|
Frank, R. W.,
R. Gennaro,
K. Schneider,
M. Przybylski, and D. Romeo.
1990.
Amino acid sequences of two proline-rich bactenecins. Antimicrobial peptides of bovine neutrophils.
J. Biol. Chem.
265:18871-18874[Abstract/Free Full Text].
|
| 11.
|
Frohm, M.,
B. Agerberth,
G. Ahangari,
M. Stahle-Backdahl,
S. Liden,
H. Wigzell, and G. H. Gudmundsson.
1997.
The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders.
J. Biol. Chem.
272:15258-15263[Abstract/Free Full Text].
|
| 12.
|
Frohm, N. M.,
B. Sandstedt,
O. Sorensen,
G. Weber,
N. Borregaard, and M. Stahle-Backdahl.
1999.
The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6.
Infect. Immun.
67:2561-2566[Abstract/Free Full Text].
|
| 13.
|
Gennaro, R.,
M. Scocchi,
L. Merluzzi, and M. Zanetti.
1998.
Biological characterization of a novel mammalian antimicrobial peptide.
Biochim. Biophys. Acta
1425:361-368[Medline].
|
| 14.
|
Gennaro, R., and M. Zanetti.
2000.
Structural features and biological activities of the cathelicidin-derived antimicrobial peptides.
Biopolymers
55:31-49[CrossRef][Medline].
|
| 15.
|
Harwig, S. S.,
V. N. Kokryakov,
K. M. Swiderek,
G. M. Aleshina,
C. Zhao, and R. I. Lehrer.
1995.
Prophenin-1, an exceptionally proline-rich antimicrobial peptide from porcine leukocytes.
FEBS Lett.
362:65-69[CrossRef][Medline].
|
| 16.
|
Harwig, S. S.,
A. Waring,
H. J. Yang,
Y. Cho,
L. Tan, and R. I. Lehrer.
1996.
Intramolecular disulfide bonds enhance the antimicrobial and lytic activities of protegrins at physiological sodium chloride concentrations.
Eur. J. Biochem.
240:352-357[Medline].
|
| 17.
|
Huttner, K. M.,
M. R. Lambeth,
H. R. Burkin,
D. J. Burkin, and T. E. Broad.
1998.
Localization and genomic organization of sheep antimicrobial peptide genes.
Gene
206:85-91[CrossRef][Medline].
|
| 18.
|
Johnson, W. C., Jr.
1990.
Protein secondary structure and circular dichroism: a practical guide.
Proteins
7:205-214[CrossRef][Medline].
|
| 19.
|
Kohashi, O.,
T. Ono,
K. Ohki,
T. Soejima,
T. Moriya,
A. Umeda,
Y. Meno,
K. Amako,
S. Funakosi, and M. Masuda.
1992.
Bactericidal activities of rat defensins and synthetic rabbit defensins on Staphylococci, Klebsiella pneumoniae (Chedid, 277, and 8N3), Pseudomonas aeruginosa (mucoid and nonmucoid strains), Salmonella typhimurium (Ra, Rc, Rd, and Rd of LPS mutants) and Escherichia coli.
Microbiol. Immunol.
36:369-380[Medline].
|
| 20.
|
Kokryakov, V. N.,
S. S. Harwig,
E. A. Panyutich,
A. A. Shevchenko,
G. M. Aleshina,
O. V. Shamova,
H. A. Korneva, and R. I. Lehrer.
1993.
Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins.
FEBS Lett.
327:231-236[CrossRef][Medline].
|
| 21.
|
Lehrer, R. I.,
A. Barton, and T. Ganz.
1988.
Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in E. coli by multiple-wavelength spectrophotometry.
J. Immunol. Methods
108:153-158[CrossRef][Medline].
|
| 22.
|
Lehrer, R. I.,
M. Rosenman,
S. S. Harwig,
R. Jackson, and P. Eisenhauer.
1991.
Ultrasensitive assays for endogenous antimicrobial polypeptides.
J. Immunol. Methods
137:167-173[CrossRef][Medline].
|
| 23.
|
Lim, J. K.,
L. Saliba,
M. J. Smith,
J. McTavish,
C. Raine, and P. Curtin.
2000.
Normal saline wound dressing is it really normal?
Br. J. Plast. Surg.
53:42-45[CrossRef][Medline].
|
| 24.
|
Mahoney, M. M.,
A. Y. Lee,
D. J. Brezinski-Caliguri, and K. M. Huttner.
1995.
Molecular analysis of the sheep cathelin family reveals a novel antimicrobial peptide.
FEBS Lett.
377:519-522[CrossRef][Medline].
|
| 25.
|
Malm, J.,
O. Sorensen,
T. Persson,
M. Frohm-Nilsson,
B. Johansson,
A. Bjartell,
H. Lilja,
M. Stahle-Backdahl,
N. Borregaard, and A. Egesten.
2000.
The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa.
Infect. Immun.
68:4297-4302[Abstract/Free Full Text].
|
| 26.
|
Peschel, A.,
R. W. Jack,
M. Otto,
L. V. Collins,
P. Staubitz,
G. Nicholson,
H. Kalbacher,
W. F. Nieuwenhuizen,
G. Jung,
A. Tarkowski,
K. P. van Kessel, and J. A. van Strijp.
2001.
Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with 1-lysine.
J. Exp. Med.
193:1067-1076[Abstract/Free Full Text].
|
| 27.
|
Peschel, A.,
M. Otto,
R. W. Jack,
H. Kalbacher,
G. Jung, and F. Gotz.
1999.
Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides.
J. Biol. Chem.
274:8405-8410[Abstract/Free Full Text].
|
| 28.
|
Pungercar, J.,
B. Strukelj,
G. Kopitar,
M. Renko,
B. Lenarcic,
F. Gubensek, and V. Turk.
1993.
Molecular cloning of a putative homolog of proline/arginine-rich antibacterial peptides from porcine bone marrow.
FEBS Lett.
336:284-288[CrossRef][Medline].
|
| 29.
|
Romeo, D.,
B. Skerlavaj,
M. Bolognesi, and R. Gennaro.
1988.
Structure and bactericidal activity of an antibiotic dodecapeptide purified from bovine neutrophils.
J. Biol. Chem.
263:9573-9575[Abstract/Free Full Text].
|
| 30.
|
Scocchi, M.,
S. Wang, and M. Zanetti.
1997.
Structural organization of the bovine cathelicidin gene family and identification of a novel member.
FEBS Lett.
417:311-315[CrossRef][Medline].
|
| 31.
|
Selsted, M. E.,
M. J. Novotny,
W. L. Morris,
Y. Q. Tang,
W. Smith, and J. S. Cullor.
1992.
Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils.
J. Biol. Chem.
267:4292-4295[Abstract/Free Full Text].
|
| 32.
|
Shamova, O.,
K. A. Brogden,
C. Zhao,
T. Nguyen,
V. N. Kokryakov, and R. I. Lehrer.
1999.
Purification and properties of proline-rich antimicrobial peptides from sheep and goat leukocytes.
Infect. Immun.
67:4106-4111[Abstract/Free Full Text].
|
| 33.
|
Sorensen, O.,
K. Arnljots,
J. B. Cowland,
D. F. Bainton, and N. Borregaard.
1997.
The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils.
Blood
90:2796-2803[Abstract/Free Full Text].
|
| 34.
|
Steinberg, D., and R. I. Lehrer.
1997.
Designer assays for antimicrobial peptides: disputing the "one size fits all" theory, p. 169-187.
In
W. M. Shafer (ed.), Methods in molecular biology. Humana Press, Totowa, N.J.
|
| 35.
|
Storici, P.,
M. Scocchi,
A. Tossi,
R. Gennaro, and M. Zanetti.
1994.
Chemical synthesis and biological activity of a novel antibacterial peptide deduced from a pig myeloid cDNA.
FEBS Lett.
337:303-307[CrossRef][Medline].
|
| 36.
|
Tang, Y. Q.,
J. Yuan,
C. J. Miller, and M. E. Selsted.
1999.
Isolation, characterization, cDNA cloning, and antimicrobial properties of two distinct subfamilies of alpha-defensins from rhesus macaque leukocytes.
Infect. Immun.
67:6139-6144[Abstract/Free Full Text].
|
| 37.
|
Tang, Y. Q.,
J. Yuan,
G. Osapay,
K. Osapay,
D. Tran,
C. J. Miller,
A. J. Ouellette, and M. E. Selsted.
1999.
A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins.
Science
286:498-502[Abstract/Free Full Text].
|
| 38.
|
Tossi, A.,
M. Seocchi,
M. Zanetti,
P. Storici, and R. Gennaro.
1995.
PMAP-37, a novel antibacterial peptide from pig myeloid cells. cDNA cloning, chemical synthesis and activity.
Eur. J. Biochem.
228:941-946[Medline].
|
| 39.
|
Travis, S. M.,
N. N. Anderson,
W. R. Forsyth,
C. Espiritu,
B. D. Conway,
E. P. Greenberg,
P. B. McCray, Jr.,
R. I. Lehrer,
M. J. Welsh, and B. F. Tack.
2000.
Bactericidal activity of mammalian cathelicidin-derived peptides.
Infect. Immun.
68:2748-2755[Abstract/Free Full Text].
|
| 40.
|
Turner, J.,
Y. Cho,
N. N. Dinh,
A. J. Waring, and R. I. Lehrer.
1998.
Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.
Antimicrob. Agents Chemother.
42:2206-2214[Abstract/Free Full Text].
|
| 41.
|
Woody, R. W.
1985.
Circular dichroism of peptides, p. 15-114.
In
E. R. Blout, F. A. Bovey, M. Goodman, and N. Lotan (ed.), The peptides, vol. 7. Academic Press, New York, N.Y.
|
| 42.
|
Zanetti, M.,
R. Gennaro, and D. Romeo.
1995.
Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain.
FEBS Lett.
374:1-5[CrossRef][Medline].
|
| 43.
|
Zanetti, M.,
P. Storici,
A. Tossi,
M. Scocchi, and R. Gennaro.
1994.
Molecular cloning and chemical synthesis of a novel antibacterial peptide derived from pig myeloid cells.
J. Biol. Chem.
269:7855-7858[Abstract/Free Full Text].
|
| 44.
|
Zhao, C.,
L. Liu, and R. I. Lehrer.
1994.
Identification of a new member of the protegrin family by cDNA cloning.
FEBS Lett.
346:285-288[CrossRef][Medline].
|
| 45.
|
Zlokarnik, G.,
P. A. Negulescu,
T. E. Knapp,
L. Mere,
N. Burres,
L. Feng,
M. Whitney,
K. Roemer, and R. Y. Tsien.
1998.
Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter.
Science
279:84-88[Abstract/Free Full Text].
|
Antimicrobial Agents and Chemotherapy, October 2001, p. 2695-2702, Vol. 45, No. 10
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.10.2695-2702.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Koprivnjak, T., Weidenmaier, C., Peschel, A., Weiss, J. P.
(2008). Wall Teichoic Acid Deficiency in Staphylococcus aureus Confers Selective Resistance to Mammalian Group IIA Phospholipase A2 and Human {beta}-Defensin 3. Infect. Immun.
76: 2169-2176
[Abstract]
[Full Text]
-
Zelezetsky, I., Pontillo, A., Puzzi, L., Antcheva, N., Segat, L., Pacor, S., Crovella, S., Tossi, A.
(2006). Evolution of the Primate Cathelicidin: CORRELATION BETWEEN STRUCTURAL VARIATIONS AND ANTIMICROBIAL ACTIVITY. J. Biol. Chem.
281: 19861-19871
[Abstract]
[Full Text]
-
Kurosaka, K., Chen, Q., Yarovinsky, F., Oppenheim, J. J., Yang, D.
(2005). Mouse Cathelin-Related Antimicrobial Peptide Chemoattracts Leukocytes Using Formyl Peptide Receptor-Like 1/Mouse Formyl Peptide Receptor-Like 2 as the Receptor and Acts as an Immune Adjuvant. J. Immunol.
174: 6257-6265
[Abstract]
[Full Text]
-
Chen, Q., Wade, D., Kurosaka, K., Wang, Z. Y., Oppenheim, J. J., Yang, D.
(2004). Temporin A and Related Frog Antimicrobial Peptides Use Formyl Peptide Receptor-Like 1 as a Receptor to Chemoattract Phagocytes. J. Immunol.
173: 2652-2659
[Abstract]
[Full Text]
-
Zanetti, M.
(2004). Cathelicidins, multifunctional peptides of the innate immunity. J. Leukoc. Biol.
75: 39-48
[Abstract]
[Full Text]